Christiana Stamoulis - 19 Dec 2025 Form 4 Insider Report for Keenova Therapeutics plc

Role
President and CFO
Signature
/s/ Mark Tyndall, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
19 Dec 2025
Net transactions value
$0
Form type
4
Filing time
23 Dec 2025, 17:31:09 UTC
Previous filing
17 Dec 2025
Next filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stamoulis Christiana President and CFO 675 MCDONNELL BLVD., HAZELWOOD /s/ Mark Tyndall, Attorney-in-Fact 23 Dec 2025 0001502917

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction Ordinary Shares Tax liability -18,631 -51% 17,828 19 Dec 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of restricted stock units ("RSUs"), which vested on December 15, 2025, is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.
F2 The Reporting Person received 18,371 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health. As a result, the 30,335 RSUs that vested on December 15, 2025, were adjusted to 36,459 RSUs.

Remarks:

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.